<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gao X</submitter><funding>the National Key Research and Development Program of China</funding><pagination>25</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12913845</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(1)</volume><pubmed_abstract>Radiation enteritis is a common complication in patients undergoing abdominal radiotherapy. Current management strategies face significant limitations: clinical agents like amifostine are hindered by systemic side effects and demanding administration; direct supplementation with radioprotective metabolites such as propionate suffers from low bioavailability and transient action; and conventional probiotics lack targeted therapeutic output. To address these challenges, we engineered Escherichia coli Nissle 1917 to function as a living therapeutic that continuously produces and delivers propionate directly in the gut. This propionate-engineered probiotic achieved a production yield of 181.33 ± 4.27 mg/L in vitro. In a mouse model of abdominal irradiation, this engineered bacterium alleviated</pubmed_abstract><journal>Bioresources and bioprocessing</journal><pubmed_title>Propionate-engineered probiotics reduce radiation-induced intestinal damage.</pubmed_title><pmcid>PMC12913845</pmcid><funding_grant_id>2024YFA0918500</funding_grant_id><pubmed_authors>Wu J</pubmed_authors><pubmed_authors>Zhu Z</pubmed_authors><pubmed_authors>Guo Y</pubmed_authors><pubmed_authors>Lu X</pubmed_authors><pubmed_authors>Huang H</pubmed_authors><pubmed_authors>Ji K</pubmed_authors><pubmed_authors>Liu Q</pubmed_authors><pubmed_authors>Zhao Z</pubmed_authors><pubmed_authors>Wang L</pubmed_authors><pubmed_authors>Wang P</pubmed_authors><pubmed_authors>Kang G</pubmed_authors><pubmed_authors>Gao M</pubmed_authors><pubmed_authors>Wang Q</pubmed_authors><pubmed_authors>Jia X</pubmed_authors><pubmed_authors>Gao X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Propionate-engineered probiotics reduce radiation-induced intestinal damage.</name><description>Radiation enteritis is a common complication in patients undergoing abdominal radiotherapy. Current management strategies face significant limitations: clinical agents like amifostine are hindered by systemic side effects and demanding administration; direct supplementation with radioprotective metabolites such as propionate suffers from low bioavailability and transient action; and conventional probiotics lack targeted therapeutic output. To address these challenges, we engineered Escherichia coli Nissle 1917 to function as a living therapeutic that continuously produces and delivers propionate directly in the gut. This propionate-engineered probiotic achieved a production yield of 181.33 ± 4.27 mg/L in vitro. In a mouse model of abdominal irradiation, this engineered bacterium alleviated</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Feb</publication><modification>2026-07-16T06:58:14.118Z</modification><creation>2026-07-09T13:10:59.852Z</creation></dates><accession>S-EPMC12913845</accession><cross_references><pubmed>41701295</pubmed><doi>10.1186/s40643-026-01020-9</doi></cross_references></HashMap>